Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Human Endometrial Development and Disease
share announcement

Human Endometrial Development and Disease

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Obstetrics & Gynecology".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 13693

Special Issue Editors

Prof. Dr. Anis Feki

E-Mail Website
Guest Editor
Gynecology and Obstetrics - HFR Friborg - Cantonal Hospital Hopital Cantonal de Fribourg, Fribourg, Switzerland
Interests: stem cell research and pluripotency; reproductive surgery
Special Issues, Collections and Topics in MDPI journals
Dr. Youssef Hibaoui

E-Mail Website
Guest Editor
Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
Interests: embryonic stem cells; induced pluripotent stem cells; developmental biology; disease modeling; neurodegenerative diseases; neurodevelopmental diseases; 2D and 3D cellular models; organoids; co-culture cellular systems; drug screening; personalized medicine; cellular replacement therapy and regenerative medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The endometrium is a complex multicellular tissue lining the uterus that plays a crucial role in human reproduction. This unique tissue undergoes remarkable dynamic remodeling, requiring a delicate interplay of cellular and molecular events which enable the endometrium to be receptive for embryo implantation. Defects in endometrium remodeling and function can lead to the development of various types of disorders including infertility, pregnancy disorders, endometriosis and endometrial cancers. In this respect, little is known regarding the molecular and the cellular mechanisms involved in this dynamic remodeling in both physiological and pathological conditions. The main obstacle of such studies is the lack of accurate models. 

Considering this, there is a constant need in biomedical research and in translational medicine for accurate systems that are capable of modeling human endometrial development and disease. In this regard, organoids and stem cell derived endometrial tissues emerge as powerful tools for disease modeling, drug screening and regenerative medicine.

This Special Issue on “Human endometrial development and disease” considers original research articles, review articles, commentaries and perspectives from all areas of endometrial research, stem cell biology, and organoid research, including—but not limited to—organoids from pluripotent stem cells or primary tissues as disease models, for developmental biology, for drug testing, for tissue engineering approaches, mathematical models, and tissue regeneration. Two-dimensional cellular models or co-culture cellular systems including endometrial cells with other cell types (immune cells, vascular cells, trophoblast cells and others) will be also considered for publication in this topic.

Prof. Dr. Anis Feki
Dr. Youssef Hibaoui
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • endometrium
  • developmental biology
  • disease modeling
  • endometrial diseases
  • endometrial organoids
  • 2D cellular models
  • co-culture cellular systems
  • drug screening
  • personalized medicine regenerative medicine

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

13 pages, 1636 KiB  
Review
Endometrial Cancer Patient-Derived Xenograft Models: A Systematic Review
by Tomohito Tanaka, Ruri Nishie, Shoko Ueda, Shunsuke Miyamoto, Sousuke Hashida, Hiromi Konishi, Shinichi Terada, Yuhei Kogata, Hiroshi Sasaki, Satoshi Tsunetoh, Kohei Taniguchi, Kazumasa Komura and Masahide Ohmichi
J. Clin. Med. 2022, 11(9), 2606; https://doi.org/10.3390/jcm11092606 - 06 May 2022
Cited by 4 | Viewed by 1922
Abstract
Background: Because patient-derived xenograft (PDX) models resemble the original tumors, they can be used as platforms to find target agents for precision medicine and to study characteristics of tumor biology such as clonal evolution and microenvironment interactions. The aim of this review was [...] Read more.
Background: Because patient-derived xenograft (PDX) models resemble the original tumors, they can be used as platforms to find target agents for precision medicine and to study characteristics of tumor biology such as clonal evolution and microenvironment interactions. The aim of this review was to identify articles on endometrial cancer PDXs (EC-PDXs) and verify the methodology and outcomes. Methods: We used PubMed to research and identify articles on EC-PDX. The data were analyzed descriptively. Results: Post literature review, eight studies were selected for the systematic review. Eighty-five EC-PDXs were established from 173 patients with EC, with a total success rate of 49.1%. A 1–10 mm3 fragment was usually implanted. Fresh-fragment implantation had higher success rates than using overnight-stored or frozen fragments. Primary tumors were successfully established with subcutaneous implantation, but metastasis rarely occurred; orthotopic implantation via minced tumor cell injection was better for metastatic models. The success rate did not correspond to immunodeficiency grades, and PDXs using nude mice reduced costs. The tumor growth period ranged from 2 weeks to 13 months. Similar characteristics were observed between primary tumors and PDXs, including pathological findings, gene mutations, and gene expression. Conclusion: EC-PDXs are promising tools for translational research because they closely resemble the features of tumors in patients and retain molecular and histological features of the disease. Full article
(This article belongs to the Special Issue Human Endometrial Development and Disease)
►▼ Show Figures

Figure 1

35 pages, 3748 KiB  
Review
Canonical TGFβ Signaling and Its Contribution to Endometrial Cancer Development and Progression—Underestimated Target of Anticancer Strategies
by Piotr K. Zakrzewski
J. Clin. Med. 2021, 10(17), 3900; https://doi.org/10.3390/jcm10173900 - 30 Aug 2021
Cited by 14 | Viewed by 2772
Abstract
Endometrial cancer is one of the leading gynecological cancers diagnosed among women in their menopausal and postmenopausal age. Despite the progress in molecular biology and medicine, no efficient and powerful diagnostic and prognostic marker is dedicated to endometrial carcinogenesis. The canonical TGFβ pathway [...] Read more.
Endometrial cancer is one of the leading gynecological cancers diagnosed among women in their menopausal and postmenopausal age. Despite the progress in molecular biology and medicine, no efficient and powerful diagnostic and prognostic marker is dedicated to endometrial carcinogenesis. The canonical TGFβ pathway is a pleiotropic signaling cascade orchestrating a variety of cellular and molecular processes, whose alterations are responsible for carcinogenesis that originates from different tissue types. This review covers the current knowledge concerning the canonical TGFβ pathway (Smad-dependent) induced by prototypical TGFβ isoforms and the involvement of pathway alterations in the development and progression of endometrial neoplastic lesions. Since Smad-dependent signalization governs opposed cellular processes, such as growth arrest, apoptosis, tumor cells growth and differentiation, as well as angiogenesis and metastasis, TGFβ cascade may act both as a tumor suppressor or tumor promoter. However, the final effect of TGFβ signaling on endometrial cancer cells depends on the cancer disease stage. The multifunctional role of the TGFβ pathway indicates the possible utilization of alterations in the TGFβ cascade as a potential target of novel anticancer strategies. Full article
(This article belongs to the Special Issue Human Endometrial Development and Disease)
►▼ Show Figures

Figure 1

12 pages, 296 KiB  
Review
Current and Prospective Treatment of Adenomyosis
by Fady I. Sharara, Mira H. Kheil, Anis Feki, Sara Rahman, Jordan S. Klebanoff, Jean Marc Ayoubi and Gaby N. Moawad
J. Clin. Med. 2021, 10(15), 3410; https://doi.org/10.3390/jcm10153410 - 30 Jul 2021
Cited by 20 | Viewed by 8148
Abstract
(1) Background: Adenomyosis is a poorly understood entity which makes it difficult to standardize treatment. In this paper we review and compare the currently approved medical and surgical treatments of adenomyosis and present the evidence behind them. (2) Methods: A PubMed search was [...] Read more.
(1) Background: Adenomyosis is a poorly understood entity which makes it difficult to standardize treatment. In this paper we review and compare the currently approved medical and surgical treatments of adenomyosis and present the evidence behind them. (2) Methods: A PubMed search was conducted to identify papers related to the different treatments of adenomyosis. The search was limited to the English language. Articles were divided into medical and surgical treatments. (3) Results: Several treatment options have been studied and were found to be effective in the treatment of adenomyosis. (4) Conclusions: Further randomized controlled trials are needed to compare treatment modalities and establish a uniform treatment algorithm for adenomyosis. Full article
(This article belongs to the Special Issue Human Endometrial Development and Disease)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop